Statin Therapy in Heart Failure: Potential Mechanisms of Benefit
Heart Failure, Congestive
About this trial
This is an interventional treatment trial for Heart Failure, Congestive focused on measuring Randomized Controlled Trial, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Sympathetic Nervous System, Ventricular Remodeling, Chemokines
Eligibility Criteria
Inclusion Criteria: Age≥18 years old LVEF ≤ 35%, as documented by echocardiography, radionuclide ventriculography, gated SPECT, or contrast ventriculography within past 6 months Symptomatic HF (NYHA II-IV) or current NYHA I with history of symptomatic HF within the last year Stable doses of optimal HF medical therapy, unless documented contraindication. Exclusion Criteria: Ischemic etiology of HF, defined as the presence of at least one of the following four criteria; angiographic evidence of > 50% lesion in 1 or more of the 3 major epicardial vessels; history of myocardial infarction; history of revascularization procedure; evidence of significant perfusion defect in the setting of ischemic symptoms. Clinical indication for statin treatment - coronary artery, cerebrovascular, or peripheral vascular disease Major cardiovascular event or surgical procedure within past 8 weeks LDL<70 mg/dL HF secondary to congenital heart disease or uncorrected valvular disease Treatment with statin within past 2 months Pregnancy Contraindication to statin: moderate liver disease, AST/ALT > 150 U/ L, known hypersensitivity Likely to receive heart transplant within 3 months Known peripheral or autonomic neuropathy
Sites / Locations
- Ahmanson-UCLA Cardiomyopathy Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
active treatment
placebo
atorvastatin 10mg QD x 3 months
matched placebo QD x 3 months